Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT06727422 is registered in ClinicalTrials.gov with Mark Pimentel, MD as lead sponsor.

NCT NCT06727422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06727422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo- Controlled, Multicenter Study to Assess the Safety, Efficacy and Pharmacokinetics of RNIB21 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Lead sponsor
Mark Pimentel, MD
Phase
Phase 2
Overall status
Recruiting
Start date
February 4, 2026
Completion date
January 1, 2027
Enrollment
225 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibs (irritable bowel syndrome), ibs-d (diarrhea-predominant)